New treatment option for neovascular age-related macular degeneration

View source ↗

Summary

EMA announces Susvimo as a new treatment option for neovascular age-related macular degeneration, delivered via an ocular implant to reduce the frequency of int…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• SUSVIMO (Ranibizumab)

Snippet

Susvimo is delivered over time via an ocular implant, reducing the need for frequent intravitreal injections